Clinical Trial Update: Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients

View source ↗

Summary

A clinical trial investigating the role of hepatocyte SLAMF3 receptor and MDR proteins in sorafenib resistance in hepatocellular carcinoma patients has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Hepatocyte Receptor, Hepatocellular Carcinoma | Status: WITHDRAWN